Filing Flows › Vertex Pharmaceuticals (VRTX) › CASGEVY revenue
Vertex Pharmaceuticals (VRTX) CASGEVY revenue by quarter
Vertex Pharmaceuticals' CASGEVY revenue was $99.2M in Q3 2026 (third quarter 2026), +30% from Q2 2026. Over the last 4 quarters it ranged from $30.4M (Q2 2025) to $99.2M (Q3 2026).
| Quarter | CASGEVY revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $99.2M | +30% | — |
| Q2 2026 | $76.4M | +78% | +151% |
| Q1 2026 | $42.9M | +41% | — |
| Q2 2025 | $30.4M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' CASGEVY revenue?
Vertex Pharmaceuticals' CASGEVY revenue was $99.2M in Q3 2026 (third quarter 2026), +30% from Q2 2026.
How has Vertex Pharmaceuticals' CASGEVY revenue changed?
Over the last 4 quarters it ranged from $30.4M (Q2 2025) to $99.2M (Q3 2026).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →